ArticleFrontiers in public health2026
Clinical epidemiology of herpes zoster and postherpetic neuralgia in Barcelona (Spain). A single-center study.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Risk prediction models for postherpetic neuralgia: a systematic review and meta-analysis.Frontiers in neurologyPooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Varicella-zoster virus is an alphaherpesvirus that causes two diseases in humans: chickenpox, the primary infection, and herpes zoster (HZ). Although HZ incidence has been well-documented, relatively little is known regarding the clinical-epidemiological characteristics of HZ prodromal pain, acute pain, and subacute pain. The aim of the study was to analyse the clinical-epidemiological characteristics of HZ and postherpetic neuralgia (PHN) in cases diagnosed between 2007 and 2020. Methods: We conducted a clinical-epidemiological study of cases of HZ and PHN diagnosed between 2007 and 2020 in Hospital de Sagrado Corazón (Barcelona) in the first 14 days after rash onset, analyzing age, gender, dermatomes, and pain. Pain on rash diagnosis was classified as no pain, any pain, and clinically significant pain (scores 0, 1-10, and 3-10, respectively). Results: A total of 589 cases of HZ were included, mean age of patients was 59.6 years and the female/male ratio was 1.38 and cases increased with age ( Conclusions: Patient age and pain presence and intensity on day 0 and at 30 days of HZ diagnosis are the main risk factors for PHN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.